Login

Alfiya I. Hasanova

ORCID: 0000-0002-4880-4353
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5014559131
Research Areas
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer-related Molecular Pathways
 Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study
OPENALEX - Publications 
Lyudmila Zhukova Л. В. Болотина В. В. Дворниченко Natalia Fadeeva I. P. Ganshina and 16 more Katerina S. Grechukhina Alfiya I. Hasanova Nikolay Kislov I.Yu. Kudryavtsev Alexey Manikhas Natalia E. Musaeva Alexandra A. Nizhegorodtseva Olga Sadikova Dina Sakaeva A. V. Snegovoy Daniil Stroyakovskiy Sergei Tjulandin Ekaterina A. Trishkina Liubov Yu Vladimirova Nikita Volkov Yulia V. Kostalanova

Background. The use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy is a key initial treatment for advanced luminal HER2-negative (HR+/HER2-) breast cancer. approval studies MONALEESA-2 7 demonstrated the efficacy safety ribociclib aromatase as first-line post- premenopausal patients. In Phase lllb CompLEEment-1 study, same regimen was evaluated an extended patient population terms both efficacy. article presents analysis data from subgroup...

10.26442/18151434.2024.1.202595 article EN Journal of Modern Oncology 2024-03-05
Coming Soon ...